Evidence map›Paper›PMID 42818232›Full record

ArticlebioRxiv : the preprint server for biology2026

CYTOKINE SIGNALING REGULATES MULTIPLE STAGES OF GAMMA-HERPESVIRUS INFECTION IN MYELOID CELLS.

Rachael E Kostelecky, Gabrielle Vragel, Pedro Gamez, Eva M Medina, Darby G Oldenburg, Andrew Goodspeed, Christoph Weigel, Robert A Baiocchi, Eric T Clambey, Linda F van Dyk

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rachael E KosteleckyDepartment of Immunology and Microbiology, University of Colorado Denver ∣ Anschutz Medical Campus, School of Medicine, Aurora, CO 80045 USA.ORCID 0000-0002-6529-3831
Gabrielle VragelDepartment of Immunology and Microbiology, University of Colorado Denver ∣ Anschutz Medical Campus, School of Medicine, Aurora, CO 80045 USA.ORCID 0000-0001-9167-3013
Pedro GamezDepartment of Immunology and Microbiology, University of Colorado Denver ∣ Anschutz Medical Campus, School of Medicine, Aurora, CO 80045 USA.ORCID 0009-0000-3210-9690
Eva M MedinaDepartment of Biochemistry and Molecular Genetics, University of Colorado Denver ∣ Anschutz Medical Campus, School of Medicine, Aurora, CO 80045 USA.ORCID 0000-0001-6899-0213
Darby G OldenburgGundersen Medical Foundation, Emplify Health System, La Crosse, WI 54601, USA.ORCID 0000-0003-2090-7489
Andrew GoodspeedDepartment of Biomedical Informatics, University of Colorado Denver ∣ Anschutz Medical Campus, School of Medicine, Aurora, CO, 80045, USA.ORCID 0000-0001-7055-7128
Christoph WeigelDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.ORCID 0009-0005-0862-4883
Robert A BaiocchiDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-1619-4853
Eric T ClambeyDepartment of Anesthesiology, University of Colorado Denver ∣ Anschutz Medical Campus, School of Medicine, Aurora, CO 80045 USA.ORCID 0000-0002-7972-9544
Linda F van DykDepartment of Immunology and Microbiology, University of Colorado Denver ∣ Anschutz Medical Campus, School of Medicine, Aurora, CO 80045 USA.ORCID 0000-0003-2662-5554

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Predoctoral Training Program in Molecular and Cellular Biology (Supplement: Mentoring in the Research Environment)T32GM136444 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI MICHAEL A MCMURRAY, Rytis Prekeris · 2020 to 2026
$3.7M
Therapeutic targets in gammaherpesvirus infectionR01AI157201 · NIAID · UNIVERSITY OF COLORADO DENVER · PI CLAMBEY, ERIC T, VAN DYK, LINDA F. · 2021 to 2025
$2.9M
NCI NIH HHS P30 CA046934NIAID NIH HHS R01 AI157201NIGMS NIH HHS T32 GM136444
6 · The paper itself

Abstract

The gammaherpesviruses, including Epstein-Barr Virus and Kaposi's Sarcoma-associated Herpesvirus, establish lifelong infections by maintaining a balance between lytic and latent infection states. How this balance is regulated in myeloid cells, an important but understudied cell type that can achieve both infection states, remains unclear. Using the murine gammaherpesvirus 68 (MHV68) model, we show that IFNγ and IL-4 reciprocally regulate lytic infection in macrophages in a time- and JAK/STAT signaling dependent-manner, with basal JAK/STAT signaling further restricting lytic infection. Using a combination of MHV68 reporter viruses, cellular and molecular techniques, we demonstrate that IFNγ blocks lytic replication through at least two distinct mechanisms, restricting delivery to or stability of the viral genome in the nucleus and potently restricting lytic cycle progression downstream of the immediate-early viral transactivator, RTA. These findings define specific points during lytic infection where IFNγ to enforce restricted, latent-like infection in myeloid cells.

Identifiers

PMID42818232
PMCPMC13622446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.